Skip to content

Clinical Study on acupuncture treating insomnia with depression

Clinical Study on acupuncture treating insomnia with depression

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-00000481
Enrollment
Unknown
Registered
2011-05-13
Start date
2011-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

insomnia with depression

Interventions

Treatment group:Add the following treatment based on the basic treatment: do the acupuncture on Lieque and Zhaohai, retain them for 30 mins after the needling sensation is attained
bury the intradermal needle after the withdrawal. Use 2 groups of acupoints: 1. Xinshu, Shenshu
2. Danshu, Anmian, both groups are used alternately.
control group:Basic treatment, use the Siguan, Baihui and Yintang for acupuncture, after the needling sensation attained, manipulate the needle by the way of transporting qi. First the Four gates, and

Sponsors

The second affiliated hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Male and female aged 18 to 65 years old; 2. meeting the diagnosis criteria of CCMD-3 depression; 3. the first chief complaint is insomnia; 4. HAMD scores between 20 and 35; 5. patients have the clear consciousness without lingual and noopsyche impairment,education level is above the primary school, can understand the meaning the scales and cooperate with the treatment.

Exclusion criteria

Exclusion criteria: 1. Depression resulting from mental diseases or active substance or non addiction medicine; 2. People who can't understand what the scale means and can't do the efficacy evaluation; 3. Pregnant or lactating women; 4. Serious heart, brain, lung, kidney and other major medical disease and cancer patients; 5. People who can't cooperate the arrangement of the treatment.

Design outcomes

Primary

MeasureTime frame
the baseline characteristics of patients;the side effects;insomnia symptoms,and judge the efficacy result;record of taking medicine;

Secondary

MeasureTime frame
HAMD scale;PSQI scores;

Countries

China

Contacts

Public ContactWenbin Fu
drfwb63@21cn.com+86 20 81887233 34230

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026